Heron Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Heron Therapeutics Inc HRTX.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of three analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -1 cents tozero cents per share.

• Revenue rose 12.2% to $38.90 million from a year ago; analysts expected $37.42 million.

• Heron Therapeutics Inc's reported EPS for the quarter was 1 cent​.

• The company reported quarterly net income of $2.64 million.

• Heron Therapeutics Inc shares had fallen by 3.2% this quarter and gained 39.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 66.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00

This summary was machine generated from LSEG data May 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)